Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Eculizumab in Primary MPGN (EAGLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02093533
Recruitment Status : Completed
First Posted : March 21, 2014
Last Update Posted : January 17, 2018
Alexion Pharma Italy s.r.l.
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research

Brief Summary:
Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative complement pathway and familial forms for all types of MPGN have been reported suggesting that genetic abnormalities may play a predisposing role to the disease. In recent case reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex ,is a safe and effective therapy.

Condition or disease Intervention/treatment Phase
Membranoproliferative Glomerulonephritis Drug: Eculizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Start Date : March 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Arm Intervention/treatment
Experimental: Eculizumab
Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
Drug: Eculizumab
Other Name: Soliris

Primary Outcome Measures :
  1. 24hours proteinuria [ Time Frame: Changes from baseline at week 1,12,24,36,48 and 72. ]

Secondary Outcome Measures :
  1. Terminal complement complex (sC5b-9) levels [ Time Frame: Changes from baseline at 1,2, 3, 4,12,24,36,48,52,56,60 and 72 week. ]
  2. Glomerular filtration rate (GFR) measured by iohexol plasma clearance and estimated. [ Time Frame: Changes from Baseline at 1,24, 48 and 72 week. ]
  3. Time to disease progression. [ Time Frame: Up 72 week. ]

Other Outcome Measures:
  1. Number of participants with Adverse Events as a measure of safety. [ Time Frame: Participants will be followed for the duration of the study, an expected average of 72 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy-proven primary MPGN
  • Creatinine clearance >20 ml/min per 1.73m2
  • 24-hour proteinuria persistently exceeding 3,5g in adults or exceeding 40mg/h/m2 in children (or exceeding 2mg protein/mg creatinine in children spot urine samples)
  • Persistently low C3 levels in at least two consecutive evaluations
  • Persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive evaluations
  • Written informed consent (by parents or tutors if underage)

Exclusion Criteria:

  • Age ≥75 years
  • Secondary MPGN (evidence of infection, immunological disease including vasculitis, systemic diseases and proliferative disorders)
  • Evidence at kidney biopsy evaluation of severe chronic histological changes that very unlikely could benefit of eculizumab therapy
  • Concomitant steroid or immunosuppressive therapy for immuno-mediated disease
  • Pregnancy or lactating
  • Childbearing potential without effective contraception
  • Any clinically relevant condition that might affect completion of the study participation and/or confound study results
  • Inability to understand the potential risks and benefits of the study
  • Legal incapacity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02093533

Layout table for location information
Ospedale Pediatrico "Giovanni XXIII" - U:O Nefrologia
Bari, BA, Italy
A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò
Bergamo, BG, Italy
Policlinico Sant'Orsola -Malpighi - U.O.S. Nefrologia e dialisi pediatrica
Bologna, BO, Italy
Policlinico "G.Martino" - U.O. Nefrologia e Dialisi
Messina, ME, Italy
Policlinico Universitario di Padova - U.O. Nefrologia Pediatrica
Padova, PD, Italy
Ospedale Centrale
Bolzano, Italy, 39100
Policlinico "Federico II" - U.O. Nefrologia
Napoli, Italy
Ospedale degli Infermi - U.O. Nefrologia e Dialisi
Rimini, Italy
C.I. Columbus-Università Cattolica del S.Cuore - UOC Nefrologia e Dialisi
Roma, Italy
Ospedale Pediatrico "Bambin Gesù" - U.O. Nefrologia
Roma, Italy
Presidio Ospedaliero O.I.R.M. "Sant'Anna" - U.O. Nefrologia
Torino, Italy
Ospedale "Santa Chiara" - U.O. Nefrologia
Trento, Italy
Ospedale Cà Foncello - U.O. Nefrologia
Treviso, Italy
Sponsors and Collaborators
Mario Negri Institute for Pharmacological Research
Alexion Pharma Italy s.r.l.
Layout table for additonal information
Responsible Party: Mario Negri Institute for Pharmacological Research Identifier: NCT02093533    
Other Study ID Numbers: EAGLE
2013-003826-10 ( EudraCT Number )
First Posted: March 21, 2014    Key Record Dates
Last Update Posted: January 17, 2018
Last Verified: January 2018
Keywords provided by Mario Negri Institute for Pharmacological Research:
Membranoproliferative glomerulonephritis
Nephrotic syndrome
Alternative complement pathway
Complement inhibition
Additional relevant MeSH terms:
Layout table for MeSH terms
Glomerulonephritis, Membranoproliferative
Urologic Diseases
Kidney Diseases
Immune System Diseases
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs